Cingulate's (CING) shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.
The transaction involved a non-convertible, unsecured promissory note for nearly $5.5 million, with a 9% annual interest rate and an 18-month maturity, the company said.
Net proceeds will be used for working capital and general corporate purposes, the company said, adding that this capital will support clinical, manufacturing, regulatory activities, and operating costs into Q4 2025. The company aims to file the new drug application for potential approval of CTx-1301 by mid-2025.
Price: 4.94, Change: +0.84, Percent Change: +20.37
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。